Strategy | Discounted costs | Discounted QALYs | IC/IE ($/QALYs) | Cancer reduction incidence (%) | Cancer mortality reduction (%) | HPVhr incidence reduction (%) | Warts incidence reduction (%) |
---|---|---|---|---|---|---|---|
No intervention | 25.359 | 30.858 | -- | 1893.000 | 348.000 | 895,739.000 | 100,676.000 |
HPV-4 a | 101.631 | 30.872 | 5400.550f | 15.850 | 18.200 | 18.130 | 15.570 |
HPV-2 a | 103.205 | 30.859 | Dominated | 13.100 | 13.100 | 4.170 | 14.500 |
HPV-9 a | 110.203 | 30.873 | 5768.350f | 16.270 | 18.410 | 20.450 | 15.560 |
Screen1 b, c | 116.544 | 30.867 | 959,735.859h 9287.599g | 18.860 | 19.020 | 10.400 | 5.900 |
 Screen1 + HPV-4c | 193.106 | 30.880 | 6070.026f | 33.860 | 35.690 | 23.640 | 20.780 |
 Screen1 + HPV-2c | 194.301 | 30.869 | Dominated | 32.280 | 32.280 | 6.490 | 19.840 |
 Screen1 + HPV-9c | 201.724 | 30.881 | 6275.190f | 34.390 | 35.950 | 25.820 | 20.800 |
Screen2 b, d | 82.945 | 30.867 | 20,372.19g 5886.421f | 18.860 | 19.020 | 10.340 | 5.880 |
 Screen2 + HPV-4d | 159.397 | 30.880 | 6058.622f | 33.860 | 35.690 | 23.610 | 20.730 |
 Screen2 + HPV-2d | 160.713 | 30.869 | Dominated | 32.280 | 32.280 | 6.460 | 19.790 |
 Screen2 + HPV-9d | 168.002 | 30.881 | 6262.947f | 34.390 | 35.950 | 25.800 | 20.750 |
Screen3 b, e | 34.004 | 30.865 | 1171.435f 1171.435f | 18.540 | 18.860 | 8.010 | 4.100 |
 Screen3 + HPV-4e | 110.341 | 30.878 | 5865.854f | 32.750 | 35.130 | 21.650 | 19.220 |
 Screen3 + HPV-2e | 111.804 | 30.866 | Dominated | 31.170 | 31.720 | 3.890 | 18.280 |
 Screen3 + HPV-9e | 118.927 | 30.879 | 6098.722f | 33.280 | 35.400 | 23.910 | 19.230 |